BEYOND_2A: BEYOND, figure 2A

BEYOND_2AR Documentation

BEYOND, figure 2A

Description

Kaplan-Meier digitized data from BEYOND, figure 2A (PMID 26014294). A reported sample size of 276 for a primary endpoint of PFS in prostate cancer.

Usage

BEYOND_2A

Format

A data frame of 276 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (bev_cp, placebo_cp)

Source

Zhou C, Wu Y-L, Chen G, et al. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2197–204.

Examples

summary(BEYOND_2A)

kmplot(BEYOND_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.